Not available
Quote | BeiGene Ltd. (NASDAQ:BGNE)
Last: | $148.56 |
---|---|
Change Percent: | -2.97% |
Open: | $148.4 |
Close: | $148.56 |
High: | $152.83 |
Low: | $146.16 |
Volume: | 407,441 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | BeiGene Ltd. (NASDAQ:BGNE)
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
Multiple presentations to showcase the efficacy and safety of BRUKINSA ® across a range of B-cell malignancies Company to present three-year data from RATIONALE-306 study of TEVIMBRA ® in advanced or metastatic esophageal squamous cell carcinoma (ESCC) Be...
Message Board Posts | BeiGene Ltd. (NASDAQ:BGNE)
Subject | By | Source | When |
---|---|---|---|
BGNE having a nice bounce and a good, | MiamiGent | investorshub | 07/05/2023 7:28:03 PM |
Thoughts on where this is headed? | StockLearner2011 | investorshub | 07/03/2023 9:49:33 PM |
Found an interesting article | luke424 | investorshub | 06/30/2023 1:45:08 AM |
$BGNE must see | StockLearner2011 | investorshub | 06/28/2023 1:49:55 AM |
here we go bulls news is here | StockLearner2011 | investorshub | 06/22/2023 3:12:55 PM |
News, Short Squeeze, Breakout and More Instantly...
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
Multiple presentations to showcase the efficacy and safety of BRUKINSA ® across a range of B-cell malignancies Company to present three-year data from RATIONALE-306 study of TEVIMBRA ® in advanced or metastatic esophageal squamous cell carcinoma (ESCC) Be...
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday. Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply duri...
Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-naïve and relapsed NSCLC Decision represents tislelizumab’s second approval in the region BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 0...